中国药房2025，Vol.36Issue(9)：1025-1029,5.DOI:10.6039/j.issn.1001-0408.2025.09.01
《骨质疏松症临床治疗生物制剂循证用药指南》推荐意见外审:一项横断面调查
External review of the recommendations of the Guidelines for Evidence-based Use of Biological Agents for the Clinical Treatment of Osteoporosis:a cross-sectional survey
摘要
Abstract
OBJECTIVE To assess the scientific rigor,clarity and feasibility of the recommendations of the Guidelines for Evidence-based Use of Biological Agents for the Clinical Treatment of Osteoporosis(hereinafter referred to as the Guideline)through external review,in order to further revise and improve the Guideline recommendations.METHODS This study employed a cross-sectional survey research design,a convenience sampling method was adopted to select frontline medical workers in the field of osteoporosis(including clinical doctors,clinical pharmacists,and nurses)as well as patients or their family members.External review was conducted through a combination of closed-ended and open-ended electronic questionnaires to get feedback from them on the appreciation,clarity and feasibility of the 32 preliminary recommendations in the Guideline.RESULTS A total of 90 external review subjects from 15 hospitals were collected,including 45 clinical doctors,15 clinical pharmacists,15 nurses and 15 patients or their family members.The overall appreciation degree of recommendations was 99.38%,the overall clarity degree of recommendations was 98.92%,and the overall feasibility degree of recommendations was 99.65%.At the same time,111 subjective suggestions were collected,which provided an important reference for the further improvement of the Guideline recommendations.Based on the above feedback,the Guideline steering committee and core expert group revised the wording of 12 draft recommendations without deletion,and finally determined 32 recommendations.CONCLUSIONS The external review provides an important basis for the final formation of the Guideline,further improves the scientific rigor,clarity and feasibility of the recommendations,and ensures the standardization,practicality and implementability of the Guideline.关键词
骨质疏松症/生物制剂/循证用药指南/外审/推荐意见Key words
osteoporosis/biological agent/evidence-based medication guideline/external review/recommendations分类
药学引用本文复制引用
余玲玲,张伶俐,赵荣生,刘爽,宋再伟,易秋莎,张玉,缪丽燕,章振林,宋纯理,陈耀龙..《骨质疏松症临床治疗生物制剂循证用药指南》推荐意见外审:一项横断面调查[J].中国药房,2025,36(9):1025-1029,5.基金项目
国家自然科学基金项目(No.72304007) （No.72304007）
北京市卫生健康科技成果和适宜技术推广项目(No.BHTPP2024007) （No.BHTPP2024007）
